AST487 (also known as NVP- AST487) is a novel and potent inhibitor of RET kinase with anticancer activity.

BBT-594 (also known as NVP-BBT594) is a novel, potent and selective receptor tyrosine kinase RET inhibitor used for cancer treatment.

Selpercatinib (LOXO-292; ARRY-192; Retevmo) is a potent,orally bioavailable and highly selective RET (REarranged during Transfection) tyrosin kinase inhibitor with IC50 of 14.0 nM, 24.1 nM, and 530.7 nM for RET (WT), RET (V804M), and RET (G810R), respectively.

WHI-P180 (also known as Janex 3) is a multi-kinase inhibitor which inhibits RET, KDR and EGFR with IC50s of 5 nM, 66 nM and 4 μM, respectively.

GSK3179106 is a novel, potent, selective, and gut-restricted RET kinase inhibitor with an IC50 of 0.4 nM.

RETV804M kinase inhibitor (Compound 13) is a novel and potent inhibitor of RETV804M kinase, which is the anticipated drug-resistant mutant of RET kinase.

Pralsetinib (GAVRETO; BLU667; BLU-667) is a novel, highly potent, selective, FDA approved RET inhibitor with anticancer activity.